OBJECTIVE: Compulsive hoarding, found in many patients with obsessive-compulsive disorder (OCD), has been associated with poor response to serotonin reuptake inhibitor (SRI) medications in some reports. However, no prior study has quantitatively measured response to standardized pharmacotherapy in compulsive hoarders. We sought to determine whether compulsive hoarders would respond as well as non-hoarding OCD patients to the SRI, paroxetine. METHODS: Seventy-nine patients with OCD (32 patients with the compulsive hoarding syndrome and 47 patients without prominent hoarding symptoms) were treated openly with paroxetine (mean dose 41.6+/-12.8 mg/day; mean duration 80.4+/-23.5 days) according to a standardized protocol, from 3/1993 to 7/2005. All subjects were free of psychotropic medication for at least four weeks prior to study entry. No psychotherapy or psychotropic medications except paroxetine were allowed during the study period. Subjects were assessed before and after treatment with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Scale (Ham-A), Global Assessment Scale (GAS), and Clinical Global Impression/Improvement (CGI) scale. RESULTS: Both compulsive hoarders and non-hoarding OCD patients improved significantly with treatment (p<0.001), with nearly identical changes in Y-BOCS, HDRS, Ham-A, and GAS scores. There were no significant differences between groups in the proportions of patients who completed or responded to treatment. Hoarding symptoms improved as much as other OCD symptoms. CONCLUSIONS: Compulsive hoarders responded as well to paroxetine treatment as non-hoarding OCD patients, suggesting that SRI medications are effective for compulsive hoarding. Controlled trials of SRI medications for compulsive hoarding are now warranted.
OBJECTIVE:Compulsive hoarding, found in many patients with obsessive-compulsive disorder (OCD), has been associated with poor response to serotonin reuptake inhibitor (SRI) medications in some reports. However, no prior study has quantitatively measured response to standardized pharmacotherapy in compulsive hoarders. We sought to determine whether compulsive hoarders would respond as well as non-hoarding OCDpatients to the SRI, paroxetine. METHODS: Seventy-nine patients with OCD (32 patients with the compulsive hoarding syndrome and 47 patients without prominent hoarding symptoms) were treated openly with paroxetine (mean dose 41.6+/-12.8 mg/day; mean duration 80.4+/-23.5 days) according to a standardized protocol, from 3/1993 to 7/2005. All subjects were free of psychotropic medication for at least four weeks prior to study entry. No psychotherapy or psychotropic medications except paroxetine were allowed during the study period. Subjects were assessed before and after treatment with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Scale (Ham-A), Global Assessment Scale (GAS), and Clinical Global Impression/Improvement (CGI) scale. RESULTS: Both compulsive hoarders and non-hoarding OCDpatients improved significantly with treatment (p<0.001), with nearly identical changes in Y-BOCS, HDRS, Ham-A, and GAS scores. There were no significant differences between groups in the proportions of patients who completed or responded to treatment. Hoarding symptoms improved as much as other OCD symptoms. CONCLUSIONS:Compulsive hoarders responded as well to paroxetine treatment as non-hoarding OCDpatients, suggesting that SRI medications are effective for compulsive hoarding. Controlled trials of SRI medications for compulsive hoarding are now warranted.
Authors: David Mataix-Cols; Scott L Rauch; Lee Baer; Jane L Eisen; David M Shera; Wayne K Goodman; Steven A Rasmussen; Michael A Jenike Journal: Am J Psychiatry Date: 2002-02 Impact factor: 18.112
Authors: S Erzegovesi; M C Cavallini; P Cavedini; G Diaferia; M Locatelli; L Bellodi Journal: J Clin Psychopharmacol Date: 2001-10 Impact factor: 3.153
Authors: Stefano Pallanti; Eric Hollander; Carol Bienstock; Lorrin Koran; James Leckman; Donatella Marazziti; Michele Pato; Dan Stein; Joseph Zohar Journal: Int J Neuropsychopharmacol Date: 2002-06 Impact factor: 5.176
Authors: Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman Journal: Depress Anxiety Date: 2010-06 Impact factor: 6.505
Authors: R Scott Mackin; Ofilio Vigil; Philip Insel; Alana Kivowitz; Eve Kupferman; Christina M Hough; Shiva Fekri; Ross Crothers; David Bickford; Kevin L Delucchi; Carol A Mathews Journal: Depress Anxiety Date: 2015-10-16 Impact factor: 6.505
Authors: Carolyn I Rodriguez; Helen Blair Simpson; Shang-Min Liu; Amanda Levinson; Carlos Blanco Journal: J Nerv Ment Dis Date: 2013-09 Impact factor: 2.254
Authors: Christina M Hough; Tracy L Luks; Karen Lai; Ofilio Vigil; Sylvia Guillory; Arvind Nongpiur; Shiva M Fekri; Eve Kupferman; Daniel H Mathalon; Carol A Mathews Journal: Psychiatry Res Neuroimaging Date: 2016-07-12 Impact factor: 2.376